No, not exactly. The reason they say that they will be targeting patients with drug-resistant HIV strains is because those are the ones that get really sick and end up with full blown AIDS. Those patients are prone to getting Kaposi's Sarcoma. That is what CS-TATI-1 is for, treatment of the AIDS related illness Kaposi's Sarcoma.
Although they aren't perusing an HIV cure, the wording of the PR could cause people to believe (as witnessed by some of the posts here) that they are seeking an HIV cure as opposed to a secondary illness common in AIDS patients if they read the PR quickly and not thoroughly.
News 
Market Data 
Discover 
AI
